source
- #ASCO26: Lilly's plenaries; Incyte's frontline data in lymphomaTwo plenaries related to Lilly: Researchers detailed findings from an investigator-sponsored trial using Lilly’s CDK4/6 inhibitor Verzenio in a rare cancer called dedifferentiated liposarcoma, show…Endpoints · 1mo ago↗ source
- Servier buys into muscular dystrophy with potentially $2.7B dealThe French drugmaker has agreed to acquire an experimental tablet from Edgewise Therapeutics that some bullish analysts say could eventually hit peak sales of over $2 billion.BioPharma Dive · 1mo ago↗ source
- As FDA misses deadline on electric shock ban, disability advocates speak outThe FDA has missed a self-imposed deadline to ban the use of electrical shock devices in people with intellectual disabilities.